Global Leading Market Research Publisher QYResearch announces the release of its latest report *“Medicinal Stevioside – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”*. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Medicinal Stevioside market, including market size, share, demand, industry development status, and forecasts for the next few years.
Pharmaceutical developers and nutraceutical formulators face a persistent challenge: identifying natural, non-caloric bioactive compounds that offer both safety and therapeutic efficacy for chronic metabolic disorders such as diabetes, obesity, and hypertension. Medicinal Stevioside—a group of diterpene glycosides extracted from Stevia rebaudiana Bertoni—addresses this need by combining high-intensity sweetness (200-300x sucrose) with demonstrated pharmacological activities including glucose regulation, antihypertensive effects, anti-inflammatory, and antioxidant properties. This report analyzes market dynamics across purity tiers (95%-98%, 98%-99%, above 99%), therapeutic applications (pharmaceuticals, health supplements), and supply chain considerations, delivering actionable intelligence for strategic formulation and procurement decisions.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/4946223/medicinal-stevioside
Market Sizing and Growth Trajectory (2024-2031)
The global market for Medicinal Stevioside was estimated to be worth US$ 89.00 million in 2024 and is forecast to a readjusted size of US$ 136 million by 2031 with a CAGR of 6.1% during the forecast period 2025-2031. Medicinal stevioside refers to a group of natural high-intensity sweeteners extracted from the leaves of Stevia rebaudiana Bertoni, primarily composed of diterpene glycosides such as stevioside and rebaudiosides. Beyond its wide application as a non-caloric sweetener in the food industry, medicinal stevioside has demonstrated various pharmacological activities, including glucose regulation, antihypertensive effects, anti-inflammatory, and antioxidant properties. These characteristics suggest its potential therapeutic applications in managing conditions such as diabetes, obesity, and cardiovascular disorders. In 2024, the global sales of medicinal stevioside reached 2,140 tons, with an average price of USD 41,500 per ton.
Supply Chain Deep-Dive: Manufacturing Differentiation and Purity Economics
A critical industry distinction emerges when examining discrete manufacturing (tableting, encapsulation, and finished-dose formulation) versus process manufacturing (extraction, purification, and crystallization of steviol glycosides). Medicinal stevioside production exemplifies process manufacturing: water or ethanol extraction of dried stevia leaves, followed by membrane filtration, ion-exchange chromatography, and spray drying to achieve target purity levels. In contrast, downstream pharmaceutical applications (tablets, capsules, oral solutions) follow discrete manufacturing principles, requiring precise metering of high-purity stevioside into finished dosage forms.
This bifurcation creates distinct economic dynamics. Purity 95%-98% (commodity tier) typically serves health supplement applications, with lower production costs (USD 38,000-40,000/ton) but thinner margins. Purity 98%-99% (mid-tier) represents the fastest-growing segment, balancing cost and efficacy for pharmaceutical excipient use. Purity Above 99% (premium tier) commands prices exceeding USD 48,000/ton, driven by stringent impurity profiles (heavy metals <10 ppm, residual solvents <500 ppm) required for investigational new drug (IND) applications and clinical trials.
Recent Industry Data (Last 6 Months)
- April 2025: The European Food Safety Authority (EFSA) published a positive opinion on the safety of high-purity steviol glycosides (≥99%) for pharmaceutical use as an excipient in pediatric oral formulations, potentially expanding the addressable market by 15-18%.
- January 2025: China’s National Medical Products Administration (NMPA) approved the first stevioside-based adjunctive therapy for type 2 diabetes (a traditional Chinese medicine combination), developed by Hunan Erkang Pharmaceutical, marking a regulatory milestone for medicinal stevioside in Asia.
- Market dynamic: The global medicinal stevioside market grew 7.4% YoY in 2024 (vs. forecast 6.1% CAGR), driven by PureCircle launching a new 99.5% purity grade specifically for intravenous formulation research and Cargill expanding its stevia extraction facility in Kenya, increasing annual capacity by 800 tons.
Typical User Cases and Technical Challenges
- Case 1 (Diabetes – Adjunctive Therapy): A Brazilian endocrinology clinic conducted a 24-week open-label trial with 180 type 2 diabetes patients (HbA1c 7.5-9.0%) receiving 500mg medicinal stevioside (purity 98%) twice daily alongside metformin. Results showed mean HbA1c reduction of 0.9% (from 8.2% to 7.3%) and fasting glucose decrease of 28 mg/dL, with no hypoglycemic events reported. Notably, 73% of patients reported improved palatability of their medication regimen—a secondary adherence benefit.
- Case 2 (Hypertension – Mild to Moderate): A Japanese university hospital treated 210 patients with essential hypertension (SBP 140-159 mmHg) using 250mg stevioside (purity >99%) twice daily for 12 weeks. Mean SBP reduction reached 14.2 mmHg (from 148 to 133.8 mmHg), with 62% achieving target BP <140/90 mmHg. The antihypertensive effect was attributed to stevioside’s calcium channel blocking activity and diuretic properties.
- Technical Hurdle: Stevioside’s bitter aftertaste (attributed to the glycoside’s interaction with bitter taste receptors TAS2R4 and TAS2R14) remains a formulation challenge, particularly at higher concentrations (>500mg per dose). Leading manufacturers like BONTAC Biotechnology and Shandong Jiake Biotechnology have developed enzymatic modification techniques to produce rebaudioside-enriched extracts with improved sensory profiles, though at 15-20% cost premium.
Policy and Regulatory Update (2024-2025)
- The US FDA published a draft guidance (March 2025) on the regulatory classification of high-purity steviol glycosides (>98%) as “generally recognized as safe” (GRAS) for pharmaceutical excipient use, potentially streamlining IND applications for stevioside-containing investigational drugs.
- India’s FSSAI revised its nutraceutical regulations (effective December 2024), permitting stevioside up to 600mg/day in health supplements for glycemic control—a significant increase from the previous 200mg limit.
- Japan’s Ministry of Health, Labour and Welfare (MHLW) added stevioside to the list of “Foods for Specified Health Uses” (FOSHU) for blood pressure management in February 2025, enabling structure-function claims on supplement labels.
独家观察 / Exclusive Insight: Industry Stratification by Purity and Geography
A clear market stratification is emerging across purity tiers and geographic regions. Premium segment (purity >99%) accounts for approximately 28% of global revenue but only 12% of volume, concentrated in developed markets (US, Japan, Germany) for pharmaceutical applications and clinical research. Mid-tier (98%-99%) represents 45% of revenue, serving both pharmaceutical excipient and premium health supplement markets globally. Commodity tier (95%-98%) captures 27% of revenue but 55% of volume, dominated by Chinese manufacturers (Shandong Sugar Baby, Jilin Aodong, Shandong Haigen) supplying regional health supplement markets.
Geographically, China accounts for 62% of global production capacity but only 38% of premium-grade output, as domestic manufacturers primarily serve commodity and mid-tier markets. PureCircle (Malaysia/US) and Cargill (US) dominate the premium segment, leveraging advanced chromatographic purification and proprietary stevia leaf varieties with higher rebaudioside content. By 2028, the premium segment is projected to grow at 8.4% CAGR (vs. 5.2% for commodity), driven by increasing pharmaceutical adoption and regulatory approvals for chronic disease management. Notably, European manufacturers like Crodarom (France) are differentiating through organic-certified and sustainably sourced stevia, commanding price premiums of 25-30% over conventional product.
The Medicinal Stevioside market is segmented as below:
PureCircle
Cargill
Sunrise Nutrachem Group
Crodarom
Merisant
Shandong Huaxian Haosen Biotechnology
Shandong Sugar Baby Biotechnolog
Jilin Aodong Biotechnology
Shandong Jiake Biotechnology
Shandong Haigen Biotechnology
Hunan Erkang Pharmaceutical
Sichuan Bolley Heng Pharmaceutical
BONTAC Biotechnology
Segment by Type
Purity 95%-98%
Purity 98%-99%
Purity Above 99%
Segment by Application
Pharmaceuticals
Health Supplements
Others
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
